Acorda Value Stock - Dividend - Research Selection
Acorda Therapeutics
ISIN: US00484M6012, WKN: A2QLBW
Market price: 0,55 USD
Acorda Therapeutics Fundamental data and company key figures of the share
| Annual reports in USD | |||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Key figures | 21-03-2022 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Cash flow | |||||||||||||||||||||||||||||||||||||||||||||||||
| Net operating cash flow | -41.348.000 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Capital Expenditures | -165.000 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Free cash flow | -41.513.000 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Balance sheet | |||||||||||||||||||||||||||||||||||||||||||||||||
| Total Equity | 151.137.000 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Liabilities & Shareholders equity | 455.470.000 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Income statement | |||||||||||||||||||||||||||||||||||||||||||||||||
| Net income | -103.954.000 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Eps (diluted) | -9,790 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Diluted shares outstanding | 10.621.000 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Net sales/revenue | 129.071.000 | ||||||||||||||||||||||||||||||||||||||||||||||||
✓ NEW Fundamental API Access to 500 data points per month
✓ Fundamental data up to 25 years
✓ Comparison to all other stocks by the FScore
✓ Time saving!
How our site works ...
✓ Non-binding 7 days without automatic subscription
✓ No termination required after the free week
✓ Finanzoo fundamental analysis
✓ Data updated daily
✓ Virtual depots
✓ Share alarms via email
✓ Subscription can be canceled at any time at the end of the month
✓ Choice of desired shares
✓ Over 2000 stock analyzes available
✓ Bitcoin payment possible if you do not want to subscribe
Price for monthly subscription $ 19.99 / month including VAT.
| Description | Data |
|---|---|
| Symbol | ACOR |
| Market Capitalization | 5.841.550,00 USD |
| Country | United States |
| Indices | NASDAQ Comp.,Russell 3000 |
| Sectors | Biotechnology |
| Raw Data Source | US GAAP in Millionen USD |
| Stock Split | 2021-01-04,1.000000/6.000000 |
| Internet | www.acorda.com |
Description of the company
Acorda Therapeutics, Inc. (Acorda) is a commercial-stage biopharmaceutical company. The Company is engaged in the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis (MS), spinal cord injury (SCI), and other disorders of the nervous system. Ampyra (dalfampridine) is an extended release tablet formulation of dalfampridine (4-aminopyridine, 4-AP). It also sells Zanaflex Capsules and Zanaflex tablets, which contain tizanidine hydrochloride, a short-acting drug for the management of spasticity. Ampyra is marketed as Fampyra outside the United States by Biogen Idec International GmbH (Biogen Idec). On February 6, 2012, the Company launched tizanidine hydrochloride capsules, an authorized generic version of Zanaflex Capsules under an agreement with Watson Pharma, Inc. In December 2012, the Company acquired Neuronex, Inc.